BRCA MASTR Dx by Multiplicom N.V

Manufacturer Multiplicom N.V
A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 93... Read more


BRCA MASTR Dx by Multiplicom N.V product image
BRCA MASTR Dx

The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.



0 Scientists have reviewed this product


Write the First Review

No Reviews

A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS

The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.

Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 93 amplicons (289-430 bp) are included, for complete exon coverage of all coding sequences of the BRCA 1&2 genes. The assay is compatible with all current Massively Parallel Sequencing (MPS) platforms, giving you the flexibility to choose your preferred method.


BRCA MASTR Dx Advantages:

  • Highly efficient workflow - Ready-to-use kit with simple-to-follow protocols for various MPS platforms.
  • Uniform coverage - 99.9% amplicons detected > 0.2X mean coverage.
  • High target specificity - 99.85% on target bases ~30 of intronic flanking sequence.
  • Low amount of DNA required - 20-50 ng per multiplex PCR reaction.